Pharvaris reported that deucrictibant met primary and secondary endpoints in a pivotal Phase 3 study as an on‑demand treatment for hereditary angioedema (HAE). The company said symptom relief began rapidly and complete resolution times beat placebo, positioning the oral drug as a competitor to KalVista’s recently approved Ekterly. Pharvaris plans regulatory filings in the first half of 2026 and is developing an extended‑release formulation for prophylaxis. Analysts note the HAE market is receptive to new oral options and that Pharvaris’ faster median onset and shorter time to full resolution could differentiate the product commercially.